Median in Medical Technology
Navigation Links
Median in Medical Technology
... (pemetrexed) was well tolerated and resulted in median progression-free survival of 3.3 months.
... grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was delivered in each cohort.
... patients were alive at time of data presentation. median progression free survival was 3.3 months.
...
... shrinkage (95% confidence interval: 26-41%). The median time to disease progression for all 145 patients was 4.3 months (95% CI; 3.6-5.9 months) and the median duration of response for the 48 responders was ... despite prior treatment. Patients had received a median of four prior therapies (between one and 15 ...
... cell (CTC) counts. New findings include the median time to PSA progression, which was 6.1 months for post-chemotherapy patients, with the median time not yet reached for chemotherapy-naive patients. In addition, the median time to radiographic progression was 6.6 months ...
... vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom ... median mg/m2 median mg/m2 1 68 ...
... due to a new malignancy on day 6. The median prior treatment regimens was two, with prior ... grade 3/4 adverse events. Best response and median time to progression of capecitabine + perifosine ... N CR PR ORR Wks CBR median TTP N(%) N(%) N(%) ...
... due to a new malignancy on day 6. The median prior treatment regimens was two, with prior ... grade 3/4 adverse events. Best response and median time to progression of capecitabine + perifosine ... CR PR ORR SD > 12 CBR median TTP N(%) N(%) N(%) ...
... N PR SD > 12 wks CBR* median PFS N (%) N (%) ... with Stable Disease or Partial Response The median PFS for all 46 patients was 12.5 weeks [95% CI (11.9, 19)]. The median overall survival has not been reached with 33 of ...
... OTC(R) 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of ... resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of ... When ADDERALL XR was administered alone, the median time to maximum plasma amphetamine concentration ...
... in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding ... dose levels. At 200 mg bid (twice-daily), the median viral load reduction was 2.4 log10 (range of 0.4 ... 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 ...
... - 31% COMPLETE RESPONSE RATE - median SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS ... full blood count recovery (CRi). The estimated median overall survival (OS) in responders was 10.5 ... the nine CRs were still alive at that time, the median OS in this group may prove to be longer. ...
... 73 patients were evaluable for response. median prior lines of therapy was 5 (range 1 - 13), ... relapsed on a bortezomib-based treatment had a median time to progression (TTP) of 8.5 months. The median TTP for all 73 evaluable study patients (both ...
... stability, the primary endpoint, showed a median of 23.7 hours for peramivir 200 mg, 37.0 hours ... from baseline in viral titer) was reduced by a median of -2.0 logs for peramivir 200 mg, -2.1 logs for ... Patients were discharged from hospital after a median of 4.0 days for peramivir 200 mg, 3.8 days for ...
... and chemotherapy) without DCVax(R)-Brain have a median survival of only 14.6 months, and less than 5% of ... patients have lived longer than the median survival of 14.6 months with existing standard of ... progression (recurrence) for longer than the median progression free survival of 6.9 months ...
... and 66 patients in the Phase II component). median prior lines of therapy was 5 (range 1 - 13), ... to 4 cycles median TTP for all study patients was 6.3 months. median TTP for responding patients has not yet been ...
... doses of Campath three times per week. After a median follow-up time of 37.9 months, the study found an ... of 30 percent among the total patient population. median PFS time was 7.7 months, and median OS time was 19.1 months. "These ...
... analysis was presented at ASH 2007. Data with a median follow up of 25.9 months were presented at this ... with the MP arm (hazard ratio =0.644, p=0.0032; median survival not yet reached in either arm). ... VcMP arm. Patients remained on VcMP therapy for a median of 46 weeks (eight cycles) out of the planned ...
... dehydrogenase (LDH), decreased 86 percent from a median of 1,814 U/L at baseline to a median of 244 U/L following 12 weeks of treatment ... treatment (P<0.001 for the pre-specified median change). Transfusion independence was ...
... chemotherapy. In Schedule A, 29 patients with a median age of 75 were enrolled and treated with 72 ... blast reductions to less than 5 percent. The median duration of response for patients achieving a CR ... is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 ...
... and high-dose arms, respectively. The median number of red blood cell transfusions (usually ... with those in the placebo arm. While baseline median platelet counts were 16,000 microliters in both ... in the placebo group. This is in contrast to median platelet counts rising to 36,000 microliters in ...
... Throughout the study, the median platelet count in the placebo group ... in the PROMACTA arm experienced a rise in their median platelet count to 36,000/microliters, with median platelet levels subsequently ranging from 52,000 ...
... prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. OGX-011 ... cancer refractory to hormone therapy showed a median survival of 27.5 months for the patients in the ...
... enrolled in SONIC were male and patients had a median age of 34-years-old, median weight of 70 kg, median disease duration of 2.3 ...
... unknown response. Responses were maintained for a median of 10.6 months (8.3-N/A). Further, the results demonstrate PFS of 9.3 months. median overall survival had not been reached at the time ... the results demonstrate PFS of 12.9 months. median overall survival had not been reached at the time ...
... surviving as long as 8 years to date. The median survival in the patients from these trials is now ... defining this standard of care achieved a median time to progression of 6.9 months and a median overall survival of 14.6 months (Stupp, et. al., ...
... (3,494 patients) or placebo (3,481 patients). median age of study participants was 67 years and 42 ... reasons. Patients were followed for a median of 3.9 years. Results from the study showed that ... LOVAZA also resulted in an increase in LDL-C by a median of 45%, from ...
... is needed. In BRIDION clinical studies, the median time to reversal of rocuronium was about three ... reversal regimen. In the SIGNAL trial, the median time to reversal of muscle relaxation to ... plus glycopyrrolate. In the AURORA trial, the median time to reversal of muscle relaxation to a TOF ...
... chemotherapy - median survival increase of 6.5 months seen for patients ... patients in the chemotherapy only group. The median survival time for all non-small cell lung cancer ... participating in the Japan Tavocept Trial, the median survival time observed for patients receiving ...
... group vs. 56% for UC group -- 67% reduction in median antibiotic use after notification of results; median of 1 day for NPF group vs. 3 days for UC group -- 100% reduction in median antibiotic use for CoNS patients ...
... of partial responses and an apparent increase in median PFS and median overall survival (OS) relative to ... rate was 75%. The median PFS was 6.4 months. The median overall survival (OS) was 21.1 months, and the 1 ... RCC is metastatic, it is difficult to treat, and median survival is between one and two years. A number ...
... that Leukine(R) (sargramostim) demonstrated a median overall survival of 65 months and increased ... cell analysis. Results showed that the median overall survival was 65 months (95 percent, CI 43-67 months). median recurrence-free survival was 5.6 months (95 ...
... (FAB) Group criteria. The median age of the patients in the subset was 71 years ... of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was ...
... with a 64 percent complete response rate and a median time to progression of 14 months. Adverse events ... whole brain radiation therapy (WBRT) improved the median time to neurologic progression from 10.0 months ... alone produces a 15% complete response rate with median time to tumor progression of about seven months ...
... defined progressive disease (4.4 years). The median OS for patients treated with ipilimumab ... with data in medical literature, in which median OS ranges from 6 to 9 months for patients with ... was 21.6%, or 8 of the 37 patients, with median OS of 12 months. Ipilimumab is being developed ...
... a statistically significant improvement in median progression-free survival (PFS), compared ... is the only renal cancer therapy proven to extend median overall survival compared with interferon-alpha ... objective response rate and overall survival. median PFS for patients treated with TORISEL 175 mg/75 ...
... shrinkage (95% confidence interval: 26-41%). The median time to disease progression for all 145 patients was 4.3 months (95% CI; 3.6-5.9 months) and the median duration of response for the 48 responders was ... despite prior treatment. Patients had received a median of four prior therapies (between one and 15 ...
... cell (CTC) counts. New findings include the median time to PSA progression, which was 6.1 months for post-chemotherapy patients, with the median time not yet reached for chemotherapy-naive patients. In addition, the median time to radiographic progression was 6.6 months ...
CuraGen Updates CR011-vcMMAE Data at ASCO
... on expression of GPNMB in patients' tumors. The median number of prior chemotherapy regimens for ... observed in 34 evaluable patients, and median duration of response of 5.3 months. The median overall progression-free survival (PFS) was 4.4 ...... vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom ... median mg/m2 median mg/m2 1 68 ...
... due to a new malignancy on day 6. The median prior treatment regimens was two, with prior ... grade 3/4 adverse events. Best response and median time to progression of capecitabine + perifosine ... N CR PR ORR Wks CBR median TTP N(%) N(%) N(%) ...
... due to a new malignancy on day 6. The median prior treatment regimens was two, with prior ... grade 3/4 adverse events. Best response and median time to progression of capecitabine + perifosine ... CR PR ORR SD > 12 CBR median TTP N(%) N(%) N(%) ...
... N PR SD > 12 wks CBR* median PFS N (%) N (%) ... with Stable Disease or Partial Response The median PFS for all 46 patients was 12.5 weeks [95% CI (11.9, 19)]. The median overall survival has not been reached with 33 of ...
... OTC(R) 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of ... resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of ... When ADDERALL XR was administered alone, the median time to maximum plasma amphetamine concentration ...
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
... with a mean follow-up period of 59 days and a median follow-up of 32 days. Noting that De Oliveira et al.(1) report the median time to CRMD infection as 14 days, and Klug et al.(2) reported a median time to infection of 52 days, the preliminary ...Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
... active patients who remain on the study have a median total follow-up of 56 months. These participants ... at baseline to 60 months post-treatment, with a median PSA slope decrease of 60 percent, 0.06 to 0.024. ... PSA doubling time prolongation and the decline in median PSA slope were greater in active patients when ...... in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding ... dose levels. At 200 mg bid (twice-daily), the median viral load reduction was 2.4 log10 (range of 0.4 ... 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 ...
... - 31% COMPLETE RESPONSE RATE - median SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS ... full blood count recovery (CRi). The estimated median overall survival (OS) in responders was 10.5 ... the nine CRs were still alive at that time, the median OS in this group may prove to be longer. ...
... 73 patients were evaluable for response. median prior lines of therapy was 5 (range 1 - 13), ... relapsed on a bortezomib-based treatment had a median time to progression (TTP) of 8.5 months. The median TTP for all 73 evaluable study patients (both ...
... stability, the primary endpoint, showed a median of 23.7 hours for peramivir 200 mg, 37.0 hours ... from baseline in viral titer) was reduced by a median of -2.0 logs for peramivir 200 mg, -2.1 logs for ... Patients were discharged from hospital after a median of 4.0 days for peramivir 200 mg, 3.8 days for ...
... and chemotherapy) without DCVax(R)-Brain have a median survival of only 14.6 months, and less than 5% of ... patients have lived longer than the median survival of 14.6 months with existing standard of ... progression (recurrence) for longer than the median progression free survival of 6.9 months ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days ... days. At the end of the treatment period, the median viral load decline was 2.5 log10 (>99%), with ... ANA598 were genotype 1a and demonstrated a median viral load decline of 1.6 log10, while five ...... and 66 patients in the Phase II component). median prior lines of therapy was 5 (range 1 - 13), ... to 4 cycles median TTP for all study patients was 6.3 months. median TTP for responding patients has not yet been ...
... doses of Campath three times per week. After a median follow-up time of 37.9 months, the study found an ... of 30 percent among the total patient population. median PFS time was 7.7 months, and median OS time was 19.1 months. "These ...
... analysis was presented at ASH 2007. Data with a median follow up of 25.9 months were presented at this ... with the MP arm (hazard ratio =0.644, p=0.0032; median survival not yet reached in either arm). ... VcMP arm. Patients remained on VcMP therapy for a median of 46 weeks (eight cycles) out of the planned ...
... dehydrogenase (LDH), decreased 86 percent from a median of 1,814 U/L at baseline to a median of 244 U/L following 12 weeks of treatment ... treatment (P<0.001 for the pre-specified median change). Transfusion independence was ...
... chemotherapy. In Schedule A, 29 patients with a median age of 75 were enrolled and treated with 72 ... blast reductions to less than 5 percent. The median duration of response for patients achieving a CR ... is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 ...
... and high-dose arms, respectively. The median number of red blood cell transfusions (usually ... with those in the placebo arm. While baseline median platelet counts were 16,000 microliters in both ... in the placebo group. This is in contrast to median platelet counts rising to 36,000 microliters in ...
... Throughout the study, the median platelet count in the placebo group ... in the PROMACTA arm experienced a rise in their median platelet count to 36,000/microliters, with median platelet levels subsequently ranging from 52,000 ...
... prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. OGX-011 ... cancer refractory to hormone therapy showed a median survival of 27.5 months for the patients in the ...
Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
... taken daily for just under two years reduced median LDL cholesterol to 55 mg/dL, down from a median of 108 mg/dL, and median hs-CRP (high-sensitivity C-reactive protein), a ...... enrolled in SONIC were male and patients had a median age of 34-years-old, median weight of 70 kg, median disease duration of 2.3 ...
... unknown response. Responses were maintained for a median of 10.6 months (8.3-N/A). Further, the results demonstrate PFS of 9.3 months. median overall survival had not been reached at the time ... the results demonstrate PFS of 12.9 months. median overall survival had not been reached at the time ...
... surviving as long as 8 years to date. The median survival in the patients from these trials is now ... defining this standard of care achieved a median time to progression of 6.9 months and a median overall survival of 14.6 months (Stupp, et. al., ...
... (3,494 patients) or placebo (3,481 patients). median age of study participants was 67 years and 42 ... reasons. Patients were followed for a median of 3.9 years. Results from the study showed that ... LOVAZA also resulted in an increase in LDL-C by a median of 45%, from ...
... is needed. In BRIDION clinical studies, the median time to reversal of rocuronium was about three ... reversal regimen. In the SIGNAL trial, the median time to reversal of muscle relaxation to ... plus glycopyrrolate. In the AURORA trial, the median time to reversal of muscle relaxation to a TOF ...
CryoCath Arctic Front(R) Results Published in JACC
... only one procedure with Arctic Front upon a median follow-up time of 12 months. "As we continue to ... applicability of Arctic Front cryoablation. The median number of applications per vein was 2.8 and the median total procedure time was 170 minutes confirming ...... chemotherapy - median survival increase of 6.5 months seen for patients ... patients in the chemotherapy only group. The median survival time for all non-small cell lung cancer ... participating in the Japan Tavocept Trial, the median survival time observed for patients receiving ...
... group vs. 56% for UC group -- 67% reduction in median antibiotic use after notification of results; median of 1 day for NPF group vs. 3 days for UC group -- 100% reduction in median antibiotic use for CoNS patients ...
... of partial responses and an apparent increase in median PFS and median overall survival (OS) relative to ... rate was 75%. The median PFS was 6.4 months. The median overall survival (OS) was 21.1 months, and the 1 ... RCC is metastatic, it is difficult to treat, and median survival is between one and two years. A number ...
... that Leukine(R) (sargramostim) demonstrated a median overall survival of 65 months and increased ... cell analysis. Results showed that the median overall survival was 65 months (95 percent, CI 43-67 months). median recurrence-free survival was 5.6 months (95 ...
... (FAB) Group criteria. The median age of the patients in the subset was 71 years ... of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was ...
... with a 64 percent complete response rate and a median time to progression of 14 months. Adverse events ... whole brain radiation therapy (WBRT) improved the median time to neurologic progression from 10.0 months ... alone produces a 15% complete response rate with median time to tumor progression of about seven months ...
... defined progressive disease (4.4 years). The median OS for patients treated with ipilimumab ... with data in medical literature, in which median OS ranges from 6 to 9 months for patients with ... was 21.6%, or 8 of the 37 patients, with median OS of 12 months. Ipilimumab is being developed ...
... a statistically significant improvement in median progression-free survival (PFS), compared ... is the only renal cancer therapy proven to extend median overall survival compared with interferon-alpha ... objective response rate and overall survival. median PFS for patients treated with TORISEL 175 mg/75 ...
Other Contentsjejunumjejunumkaryokinesisappendagesappendagesjointedkilobasekingdomkingdomkingdomkingdom
Breaking Biology News(10 mins):The impact of the diffusion of maize to the Southwestern United States 2ADA releases updated position paper on nutrient supplementation 2UAB bone center director wins distinguished service award from clinical pathology society 2Confusion over Influenzinum Clarified by the American Association of Homeopathic Pharmacists 28AAHP 29 5799 1Confusion over Influenzinum Clarified by the American Association of Homeopathic Pharmacists 28AAHP 29 5799 2Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 1Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 2Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 3Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 4Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 5Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 6Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 7Neurocrine Biosciences Reports Third Quarter 2009 Results 5796 8Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 60281 1Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 60281 2Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 60281 3
Breaking Medicine News(10 mins):Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3Health News:New Report Finds That Three in Ten California Households Cannot Afford Basic Needs 2Health News:Ophthonix Launches iZon(R) SL(TM) Polarized Lenses 2Health News:Ophthonix Launches iZon(R) SL(TM) Polarized Lenses 3Health News:Possible ovarian cancer treatment target identified 2
Other Tags[0] Researchers identify barriers to HPV vaccination uptake in low-income populations[1] New Report Finds That Three in Ten California Households Cannot Afford Basic Needs[0] Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab[0] Ophthonix Launches iZon(R) SL(TM) Polarized Lenses[0] Possible ovarian cancer treatment target identified
DuodenalDuffyDrinoxDoridenDramamineDoxepinDolophineDonnatalDonathDiureticDisopyramideDisulfiramDisaccharidaseDipyridamole
Other Tagsradiation 2radiation 3radiation 4radiation 5radiation 6radiation 7radiation 8radiation 9radiation 10undergoing 2undergoing 3undergoing 4undergoing 5undergoing 6undergoing 7undergoing 8undergoing 9undergoing 10protect 2protect 3protect 4protect 5protect 6protect 7protect 8protect 9protect 10antioxidants 2antioxidants 3antioxidants 4antioxidants 5antioxidants 6antioxidants 7antioxidants 8their 2their 3their 4their 5their 6their 7their 8their 9their 10pregnant 2pregnant 3pregnant 4pregnant 5pregnant 6pregnant 7pregnant 8pregnant 9pregnant 10tolerance 2tolerance 3enhanced 2enhanced 3enhanced 4enhanced 5enhanced 6enhanced 7enhanced 8| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |